share_log

Two Top Biotechs Forge MDMA Supply Deals For Clinical Research

Benzinga ·  Mar 26 15:35

Two separate deals hit the wires on Tuesday. One is PharmAla Biotech's (OTC:MDXXF) with Numinus Wellness (OTC:NUMIF) for a group therapy model with MDMA, the other is Optimi Health's (OTCQX:OPTHF) with Tel Aviv University for MDMA's potential effects on addiction treatment.

PharmAla Signs Sale Agreement With Numinus

PharmAla Biotech Holdings, a biotech company researching, developing and manufacturing proprietary MDMA "LaNeo" and new MDMA derivatives (aka MDXX-class molecules) entered into a binding sales agreement with Numinus Wellness to provide its GMP MDMA LaNeo for a prospective clinical trial, now holding for approval.

PharmAla's...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment